Data on Effectiveness of Morning Sickness Drug May Be Flawed

Share this content:
Data on Effectiveness of Morning Sickness Drug May Be Flawed
Data on Effectiveness of Morning Sickness Drug May Be Flawed

FRIDAY, Jan. 6, 2017 (HealthDay News) -- Pyridoxine-doxylamine (Diclectin), used to manage the nausea and vomiting associated with morning sickness, may not be as effective as once believed, according to a new analysis published online Jan. 4 in PLOS One.

Nav Persaud, M.D., and Rujun Zhang, M.D., from St. Michael's Hospital in Toronto, reviewed 36,000 pages of documents from the U.S. Food and Drug Administration, including an unpublished 1970s study and a summary of the results. The investigators also obtained other documents from Health Canada through freedom of information requests.

The original trial was done in 14 U.S. clinics among 2,308 women who experienced morning sickness during their first 12 weeks of pregnancy. The women were randomly assigned to eight groups, one of which was given a placebo and the other seven a variety of drugs, including pyridoxine-doxylamine. Data from 1,599 women were analyzed. More women rated the drugs as moderate or excellent, compared with those given a placebo. For pyridoxine-doxylamine, 14 percent gave it a moderate or excellent rating.

Persaud said the earlier study's data about the effectiveness of pyridoxine-doxylamine are shaky at best. "We found two main problems with the [unpublished] study. Data were missing for 31 percent of participants. There are questions about the integrity of the data," Persaud told HealthDay. "The approval and prescribing of this medication are based on this study. The decision to approve this medication should be revisited. The prescribing of the medication should be revisited."

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »